drugset / Trial / NCT00259311

Efficacy Study of LY2422347 to Treat Insomnia

NCT00259311 ↗

Phase 2 Completed 400 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether a compound known as LY2422347 is effective in treating people diagnosed with primary insomnia (difficulty sleeping with no other significant contributing factor, such as depression).

Timeline

Start
2005-11
Primary completion
—
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PRUVANSERIN Small molecule 5 mg —
Subject PRUVANSERIN Small molecule 15 mg —